Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 736

The DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Open access
Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R., D'Amico, Thomas A., Dilling, Thomas J., Dobelbower, M. Chris, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M., Komaki, Ritsuko, Lackner, Rudy P., Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W., Martins, Renato, Otterson, Gregory A., Patel, Jyoti D., Pisters, Katherine M., Reckamp, Karen, Riely, Gregory J., Schild, Steven E., Shapiro, Theresa A., Sharma, Neelesh, Stevenson, James, Swanson, Scott J., Tauer, Kurt, Yang, Stephen C., Gregory, Kristina, Hughes, Miranda·2016·Journal of the National Comprehensive Cancer Network

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2016.0031

Cites

306 of 306 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 306 references

Cited by

See all 736

Metadata

Authors
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M. C., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., Lin, J., Loo, B. W., Martins, R., Otterson, G. A., Patel, J. D., Pisters, K. M., Reckamp, K., Riely, G. J., Schild, S. E., Shapiro, T. A., Sharma, N., Stevenson, J., Swanson, S. J., Tauer, K., Yang, S. C., Gregory, K., & Hughes, M.
Venue
Journal of the National Comprehensive Cancer Network
Published
2016-03
Volume
14
Issue
3
Pages
255-264
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W2296139876
Cited by
736
References
306
FWCI
74.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016. https://app.cochat.ai/papers/10.6004/jnccn.2016.0031
The paper
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M. C., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., . . . Hughes, M. (2016). NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2016.0031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.